Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anaptysbio (ANAB) Consolidated Net Income (2016 - 2026)

Anaptysbio filings provide 11 years of Consolidated Net Income readings, the most recent being -$52.9 million for Q1 2026.

  • On a quarterly basis, Consolidated Net Income fell 34.47% to -$52.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$13.7 million, a 90.25% increase, with the full-year FY2025 number at -$164000.0, up 99.89% from a year prior.
  • Consolidated Net Income hit -$52.9 million in Q1 2026 for Anaptysbio, down from $62.7 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $121.4 million in Q4 2023 to a low of -$52.9 million in Q1 2026.
  • Median Consolidated Net Income over the past 5 years was -$32.9 million (2024), compared with a mean of -$17.7 million.
  • Biggest five-year swings in Consolidated Net Income: plummeted 6121.91% in 2022 and later surged 648.34% in 2023.
  • Anaptysbio's Consolidated Net Income stood at -$22.1 million in 2022, then surged by 648.34% to $121.4 million in 2023, then tumbled by 118.06% to -$21.9 million in 2024, then skyrocketed by 385.92% to $62.7 million in 2025, then crashed by 184.37% to -$52.9 million in 2026.
  • The last three reported values for Consolidated Net Income were -$52.9 million (Q1 2026), $62.7 million (Q4 2025), and $15.1 million (Q3 2025) per Business Quant data.